<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01812668</url>
  </required_header>
  <id_info>
    <org_study_id>2011-185</org_study_id>
    <secondary_id>NCI-2013-00399</secondary_id>
    <nct_id>NCT01812668</nct_id>
  </id_info>
  <brief_title>Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer</brief_title>
  <official_title>Pilot Trial of Oral Cabozantinib/XL184 in Metastatic Castrate Resistant Prostate Cancer to Explore the Changes in Bone and Tumor Imaging Related Pathways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies cabozantinib-s-malate in treating patients with&#xD;
      hormone-resistant metastatic prostate cancer. Cabozantinib-s-malate may stop the growth of&#xD;
      tumor cells by blocking some of the enzymes needed for cell growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the timing, pathophysiology, and magnitude of changes in tumor imaging and&#xD;
      pharmacodynamic markers with XL184 (cabozantinib-s-malate) treatment in metastatic castrate&#xD;
      resistant prostate cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the progression-free survival (PFS) achieved with XL184 in metastatic castrate&#xD;
      resistant prostate cancer (CRPC) patients.&#xD;
&#xD;
      II. To evaluate the feasibility of the therapy, and the toxicities associated. III. To&#xD;
      evaluate overall survival (OS) in metastatic CRPC patients post androgen deprivation therapy&#xD;
      (ADT) treated with XL-184.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive cabozantinib-s-malate orally (PO) daily in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4 weeks and then&#xD;
      periodically thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 18, 2019</completion_date>
  <primary_completion_date type="Actual">January 18, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment.</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Change in PET standard uptake value SUV levels (each value measured in g/ml). (post-treatment - pre-treatment)/pre-treatment x 100 , therefore, measured in percentage change from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>From date of registration to date of first documented disease progression, or death from any cause, assessed up to 1 year</time_frame>
    <description>Summarized via the Kaplan-Meier (K-M) survivorship estimate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Indicated Toxicities Grade 3 or Higher</measure>
    <time_frame>Up to 4 weeks post-treatment, about 2 years on average.</time_frame>
    <description>Type of toxicities graded per National Cancer Institute (NCI) CTCAE version 4.0 Summarized via their frequency distribution and point estimate of the proportion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Indicated Clinical Response Based on the RECIST Criteria 1.1</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of Participants with Indicated Clinical response based on the RECIST criteria 1.1 summarized via their frequency distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA Response Based on the RECIST Criteria 1.1</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summarized via their frequency distribution, point estimate of the proportion, and the Wilson type 80% CI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET Response Based on the RECIST Criteria 1.1</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Summarized via their frequency distribution, point estimate of the proportion, and the Wilson type 80% CI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Hormone-resistant Prostate Cancer</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <condition>Stage IV Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (cabozantinib-s-malate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cabozantinib-s-malate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (cabozantinib-s-malate)</arm_group_label>
    <other_name>BMS-907351</other_name>
    <other_name>Cometriq</other_name>
    <other_name>XL184</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fluorine F 18 d-FMAU</intervention_name>
    <description>Undergo 18F PET/FMAU PET scan</description>
    <arm_group_label>Treatment (cabozantinib-s-malate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo 18F PET/FMAU PET scan</description>
    <arm_group_label>Treatment (cabozantinib-s-malate)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cabozantinib-s-malate)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (cabozantinib-s-malate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject has histologically confirmed prostate adenocarcinoma with radiologic&#xD;
             evidence of metastases&#xD;
&#xD;
          -  If patient are on anti-androgens, these should be discontinued, at least 4 weeks prior&#xD;
             for flutamide and at least 6 weeks for bicalutamide or nilutamide&#xD;
&#xD;
          -  At least 14 days should have elapsed from prior radiation therapy to bone metastases&#xD;
             from prostate cancer&#xD;
&#xD;
          -  The patient has received a maximum of one prior chemotherapy regimen for metastatic&#xD;
             prostate cancer&#xD;
&#xD;
          -  Patients must demonstrate disease progression on or after most recent systemic&#xD;
             therapy, either by prostate-specific antigen (PSA), new bone metastases or by&#xD;
             measurable disease criteria per Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             guidelines&#xD;
&#xD;
          -  Patients should have received either luteinizing hormone-releasing hormone (LHRH)&#xD;
             analogue, or LHRH analogue and anti- androgen for metastatic prostate cancer&#xD;
&#xD;
          -  The patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0&#xD;
             or 1&#xD;
&#xD;
          -  Bisphosphonate therapy can be continued if started prior to protocol enrollment&#xD;
&#xD;
          -  Patients must have blood pressure (BP) readings &lt; 150/90 prior to enrollment&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3 without colony stimulating factor support&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert's&#xD;
             disease, bilirubin =&lt; 3.0 mg/dL&#xD;
&#xD;
          -  Serum albumin &gt;= 2.8 g/dl&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 x ULN or creatinine clearance (CrCl) &gt;= 50 mL/min; for&#xD;
             creatinine clearance estimation, the Cockcroft and Gault equation should be used&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =&lt; 2.5 x ULN if no&#xD;
             liver involvement, or =&lt; 5 x ULN with liver involvement&#xD;
&#xD;
          -  Lipase &lt; 1.5 x the upper limit of normal (except for subjects with adenocarcinoma of&#xD;
             the pancreas)&#xD;
&#xD;
          -  Urine protein/creatinine ratio (UPCR) =&lt; 1&#xD;
&#xD;
          -  Serum phosphorus &gt;= lower limit of normal (LLN)&#xD;
&#xD;
          -  The subject is capable of understanding and complying with the protocol requirements&#xD;
             and has signed the informed consent document&#xD;
&#xD;
          -  Patients participating in this trial must also be eligible and willing to sign consent&#xD;
             for participation in [2'-18F]-1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)thymine&#xD;
             (FMAU) and 18F-flouride positron emission tomography (PET) scans done under separate&#xD;
             protocols&#xD;
&#xD;
          -  Sexually active subjects (men) must agree to use medically accepted barrier methods of&#xD;
             contraception (eg, male condom, or diaphragm with spermicidal gel) during the course&#xD;
             of the study and for 4 months after the last dose of study drug(s), even if oral&#xD;
             contraceptives are also used by the female partner; all subjects of reproductive&#xD;
             potential must agree to use both a barrier method and a second method of birth control&#xD;
&#xD;
          -  Projected life expectancy of at least 6 months&#xD;
&#xD;
          -  No prior history of other malignancies in the last 3 years, except for squamous and&#xD;
             basal cell skin cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has received cytotoxic chemotherapy (including investigational cytotoxic&#xD;
             chemotherapy) or biologic agents (eg, cytokines or antibodies) within 3 weeks, or&#xD;
             nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment&#xD;
&#xD;
          -  Prior treatment with cabozantinib&#xD;
&#xD;
          -  The subject has received radiation therapy:&#xD;
&#xD;
               -  To the thoracic cavity or gastrointestinal tract within 3 months of the first&#xD;
                  dose of study treatment&#xD;
&#xD;
               -  To bone or brain metastasis within 14 days of the first dose of study treatment&#xD;
&#xD;
               -  To any other site(s) within 28 days of the first dose of study treatment&#xD;
&#xD;
          -  The subject has received radionuclide treatment within 6 weeks of the first dose of&#xD;
             study treatment&#xD;
&#xD;
          -  The subject has received prior treatment with a small molecule kinase inhibitor or a&#xD;
             hormonal therapy (including investigational kinase inhibitors or hormones) within 14&#xD;
             days or five half-lives of the compound or active metabolites, whichever is longer,&#xD;
             before the first dose of study treatment; patients receiving LHRH or&#xD;
             gonadotropin-releasing hormone (GnRH) agonists to maintain castrate levels of&#xD;
             testosterone or patients on bisphosphonate/denosumab, may be maintained on these&#xD;
             agents&#xD;
&#xD;
          -  The subject has received any other type of investigational agent within 28 days before&#xD;
             the first dose of study treatment&#xD;
&#xD;
          -  The subject has not recovered to baseline or Common Terminology Criteria for Adverse&#xD;
             Events (CTCAE) =&lt; grade 1 from toxicity due to all prior therapies except alopecia and&#xD;
             other non-clinically significant adverse events (AEs)&#xD;
&#xD;
          -  The subject has a primary brain tumor&#xD;
&#xD;
          -  The subject has active brain metastases or epidural disease (Note: Subjects with brain&#xD;
             metastases previously treated with whole brain radiation or radiosurgery or subjects&#xD;
             with epidural disease previously treated with radiation or surgery who are&#xD;
             asymptomatic and do not require steroid treatment for at least 2 weeks before starting&#xD;
             study treatment are eligible; neurosurgical resection of brain metastases or brain&#xD;
             biopsy is permitted if completed at least 3 months before starting study treatment;&#xD;
             baseline brain scans are not required to confirm eligibility)&#xD;
&#xD;
          -  The subject has prothrombin time (PT)/international normalized ratio (INR) or partial&#xD;
             thromboplastin time (PTT) test results at screening &gt;= 1.3 x the laboratory ULN&#xD;
&#xD;
          -  The subject requires concomitant treatment, in therapeutic doses, with anticoagulants&#xD;
             such as warfarin or warfarin-related agents, heparin, thrombin or Factor xabans (Xa)&#xD;
             inhibitors, or antiplatelet agents (eg, clopidogrel); low dose aspirin (=&lt; 81 mg/day),&#xD;
             low-dose warfarin (=&lt; 1 mg/day), and prophylactic low molecular weight heparin (LMWH)&#xD;
             are permitted&#xD;
&#xD;
          -  The subject has experienced any of the following within 3 months before the first dose&#xD;
             of study treatment:&#xD;
&#xD;
               -  Clinically-significant hematemesis or gastrointestinal bleeding&#xD;
&#xD;
               -  Hemoptysis of &gt;= 0.5 teaspoon (2.5 ml) of red blood&#xD;
&#xD;
               -  Any other signs indicative of pulmonary hemorrhage&#xD;
&#xD;
          -  The subject has radiographic evidence of cavitating pulmonary lesion(s)&#xD;
&#xD;
          -  The subject has tumor in contact with, invading or encasing major blood vessels&#xD;
&#xD;
          -  The subject has uncontrolled, significant intercurrent or recent illness including,&#xD;
             but not limited to, the following conditions:&#xD;
&#xD;
               -  Cardiovascular disorders including&#xD;
&#xD;
                    -  Congestive heart failure (CHF): New York Heart Association (NYHA) class III&#xD;
                       (moderate) or class IV (severe) at the time of screening&#xD;
&#xD;
                    -  Concurrent uncontrolled hypertension defined as sustained BP &gt; 140 mmHg&#xD;
                       systolic, or &gt; 90 mmHg diastolic despite optimal antihypertensive treatment&#xD;
                       (BP must be controlled at screening)&#xD;
&#xD;
                    -  Any of the following within 6 months before the first dose of study&#xD;
                       treatment:&#xD;
&#xD;
                         -  Unstable angina pectoris&#xD;
&#xD;
                         -  Clinically-significant cardiac arrhythmias&#xD;
&#xD;
                         -  Stroke (including transient ischemic attack [TIA], or other ischemic&#xD;
                            event)&#xD;
&#xD;
                         -  Myocardial infarction&#xD;
&#xD;
                         -  Thromboembolic event requiring therapeutic anticoagulation (Note:&#xD;
                            subjects with a venous filter (e.g. vena cava filter) are not eligible&#xD;
                            for this study)&#xD;
&#xD;
               -  Gastrointestinal disorders particularly those associated with a high risk of&#xD;
                  perforation or fistula formation including:&#xD;
&#xD;
                    -  Any of the following at the time of screening&#xD;
&#xD;
                         -  Intra-abdominal tumor/metastases invading gastrointestinal (GI) mucosa&#xD;
&#xD;
                         -  Active peptic ulcer disease&#xD;
&#xD;
                         -  Inflammatory bowel disease (including ulcerative colitis and Crohn's&#xD;
                            disease), diverticulitis, cholecystitis, symptomatic cholangitis or&#xD;
                            appendicitis&#xD;
&#xD;
                    -  Any of the following within 6 months before the first dose of study&#xD;
                       treatment:&#xD;
&#xD;
                         -  History of abdominal fistula&#xD;
&#xD;
                         -  Gastrointestinal perforation&#xD;
&#xD;
                         -  Bowel obstruction or gastric outlet obstruction&#xD;
&#xD;
                         -  Intra-abdominal abscess. Note: Complete resolution of an intraabdominal&#xD;
                            abscess must be confirmed prior to initiating treatment with&#xD;
                            cabozantinib even if the abscess occurred more that 6 months ago&#xD;
&#xD;
                    -  GI surgery (particularly when associated with delayed or incomplete healing)&#xD;
                       within 28 days; Note: Complete healing following abdominal surgery must be&#xD;
                       confirmed prior to initiating treatment with cabozantinib even if surgery&#xD;
                       occurred more that 28 days ago&#xD;
&#xD;
               -  Other disorders associated with a high risk of fistula formation including&#xD;
                  percutaneous endoscopic gastrostomy (PEG) tube placement within 3 months before&#xD;
                  the first dose of study therapy or concurrent evidence of intraluminal tumor&#xD;
                  involving the trachea and esophagus&#xD;
&#xD;
               -  Other clinically significant disorders such as:&#xD;
&#xD;
                    -  Active infection requiring systemic treatment&#xD;
&#xD;
                    -  Serious non-healing wound/ulcer/bone fracture&#xD;
&#xD;
                    -  History of organ transplant&#xD;
&#xD;
                    -  Concurrent uncompensated hypothyroidism or thyroid dysfunction&#xD;
&#xD;
                    -  History of major surgery within 4 weeks or minor surgical procedures within&#xD;
                       1 week before randomization&#xD;
&#xD;
          -  The subject is unable to swallow tablets&#xD;
&#xD;
          -  The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) &gt;&#xD;
             470 ms within 28 days before randomization&#xD;
&#xD;
          -  The subject has a previously identified allergy or hypersensitivity to components of&#xD;
             the study treatment formulation&#xD;
&#xD;
          -  The subject is unable or unwilling to abide by the study protocol or cooperate fully&#xD;
             with the investigator or designee&#xD;
&#xD;
          -  The subject has had evidence within 2 years of the start of study treatment of another&#xD;
             malignancy, which required systemic treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulka Vaishampayan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2013</study_first_posted>
  <results_first_submitted>February 26, 2021</results_first_submitted>
  <results_first_submitted_qc>February 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2021</results_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Elisabeth Heath</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorides</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 14, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT01812668/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Cabozantinib-s-malate)</title>
          <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.&#xD;
cabozantinib-s-malate: Given PO&#xD;
fluorine F 18 d-FMAU: Undergo 18F PET/FMAU PET scan&#xD;
positron emission tomography: Undergo 18F PET/FMAU PET scan&#xD;
pharmacological study: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Cabozantinib-s-malate)</title>
          <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.&#xD;
cabozantinib-s-malate: Given PO&#xD;
fluorine F 18 d-FMAU: Undergo 18F PET/FMAU PET scan&#xD;
positron emission tomography: Undergo 18F PET/FMAU PET scan&#xD;
pharmacological study: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="56" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment.</title>
        <description>Change in PET standard uptake value SUV levels (each value measured in g/ml). (post-treatment - pre-treatment)/pre-treatment x 100 , therefore, measured in percentage change from baseline.</description>
        <time_frame>Baseline to 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.&#xD;
cabozantinib-s-malate: Given PO&#xD;
fluorine F 18 d-FMAU: Undergo 18F PET/FMAU PET scan&#xD;
positron emission tomography: Undergo 18F PET/FMAU PET scan&#xD;
pharmacological study: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment.</title>
          <description>Change in PET standard uptake value SUV levels (each value measured in g/ml). (post-treatment - pre-treatment)/pre-treatment x 100 , therefore, measured in percentage change from baseline.</description>
          <units>percentage change from baseline</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56" lower_limit="-85" upper_limit="-5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Summarized via the Kaplan-Meier (K-M) survivorship estimate.</description>
        <time_frame>From date of registration to date of first documented disease progression, or death from any cause, assessed up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.&#xD;
cabozantinib-s-malate: Given PO&#xD;
fluorine F 18 d-FMAU: Undergo 18F PET/FMAU PET scan&#xD;
positron emission tomography: Undergo 18F PET/FMAU PET scan&#xD;
pharmacological study: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Summarized via the Kaplan-Meier (K-M) survivorship estimate.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.3" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Indicated Toxicities Grade 3 or Higher</title>
        <description>Type of toxicities graded per National Cancer Institute (NCI) CTCAE version 4.0 Summarized via their frequency distribution and point estimate of the proportion.</description>
        <time_frame>Up to 4 weeks post-treatment, about 2 years on average.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.&#xD;
cabozantinib-s-malate: Given PO&#xD;
fluorine F 18 d-FMAU: Undergo 18F PET/FMAU PET scan&#xD;
positron emission tomography: Undergo 18F PET/FMAU PET scan&#xD;
pharmacological study: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Indicated Toxicities Grade 3 or Higher</title>
          <description>Type of toxicities graded per National Cancer Institute (NCI) CTCAE version 4.0 Summarized via their frequency distribution and point estimate of the proportion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Parkinson like syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decreased ALC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>decreased platelet</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>dehydration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>foot blisters</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hyperglycemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hypophosphatemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>increased AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mandibular abscess</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mucositis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pleurisy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>urinary retention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>weight loss</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Indicated Clinical Response Based on the RECIST Criteria 1.1</title>
        <description>Number of Participants with Indicated Clinical response based on the RECIST criteria 1.1 summarized via their frequency distribution.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Patients with measurable disease</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.&#xD;
cabozantinib-s-malate: Given PO&#xD;
fluorine F 18 d-FMAU: Undergo 18F PET/FMAU PET scan&#xD;
positron emission tomography: Undergo 18F PET/FMAU PET scan&#xD;
pharmacological study: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Indicated Clinical Response Based on the RECIST Criteria 1.1</title>
          <description>Number of Participants with Indicated Clinical response based on the RECIST criteria 1.1 summarized via their frequency distribution.</description>
          <population>Patients with measurable disease</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PSA Response Based on the RECIST Criteria 1.1</title>
        <description>Summarized via their frequency distribution, point estimate of the proportion, and the Wilson type 80% CI.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.&#xD;
cabozantinib-s-malate: Given PO&#xD;
fluorine F 18 d-FMAU: Undergo 18F PET/FMAU PET scan&#xD;
positron emission tomography: Undergo 18F PET/FMAU PET scan&#xD;
pharmacological study: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PSA Response Based on the RECIST Criteria 1.1</title>
          <description>Summarized via their frequency distribution, point estimate of the proportion, and the Wilson type 80% CI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PET Response Based on the RECIST Criteria 1.1</title>
        <description>Summarized via their frequency distribution, point estimate of the proportion, and the Wilson type 80% CI.</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Cabozantinib-s-malate)</title>
            <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.&#xD;
cabozantinib-s-malate: Given PO&#xD;
fluorine F 18 d-FMAU: Undergo 18F PET/FMAU PET scan&#xD;
positron emission tomography: Undergo 18F PET/FMAU PET scan&#xD;
pharmacological study: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>PET Response Based on the RECIST Criteria 1.1</title>
          <description>Summarized via their frequency distribution, point estimate of the proportion, and the Wilson type 80% CI.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All untoward events that occur after start of therapy through 30 days after the last dose of study treatment are to be recorded, about 12 months on average.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Cabozantinib-s-malate)</title>
          <description>Patients receive cabozantinib-s-malate PO daily in the absence of disease progression or unacceptable toxicity.&#xD;
cabozantinib-s-malate: Given PO&#xD;
fluorine F 18 d-FMAU: Undergo 18F PET/FMAU PET scan&#xD;
positron emission tomography: Undergo 18F PET/FMAU PET scan&#xD;
pharmacological study: Correlative studies&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hand foot syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>elevated creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>decreased ALC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>increased ALT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>increased AST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypothyroidism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>mucositis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hoarseness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bone pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hand/foot</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>blisters</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Elisabeth Heath</name_or_title>
      <organization>Barbara Ann Karmanos Cancer Institute</organization>
      <phone>313-576-8734</phone>
      <email>heathe@karmanos.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

